Blue Goat Cyber logoBlue Goat CyberSMMedical Device Cybersecurity
    K
    Podcast · Episode 49

    How Cybersecurity Shapes Regulatory and Quality Success with Jim Goodmiller

    With Jim Goodmiller - What risks do you take when cybersecurity is left off your development roadmap? In this episode, Christian, Trevor and guest Jim Goodmiller explore how cybersecurity intersects with regulatory expectations and quality systems, creating new challenges and opportunities for MedTech

    Christian Espinosa, Founder & CEO at Blue Goat Cyber

    By Christian Espinosa, MBA, CISSP

    Founder & CEO · Blue Goat Cyber

    Listen now

    Key takeaways

    • Cybersecurity in medical devices is now integral to regulatory and quality compliance, extending beyond traditional IT concerns.
    • Medical device innovators often delay cybersecurity considerations, leading to costly last-minute vulnerability discoveries and project setbacks.
    • Implementing 'security-by-design' principles from the initial concept phase and throughout development is crucial for mitigating cybersecurity risks.
    • New technologies like AI in healthcare require extensive vetting due to potential patient harm and regulatory scrutiny, as highlighted by incidents of AI-generated harmful advice.
    • The FDA is increasing its enforcement of cybersecurity regulations, making proactive compliance essential for market approval and avoiding legal issues.
    • Legacy medical devices pose significant cybersecurity challenges, often requiring as much resource investment to secure as developing a new product.
    • Fractional engagement with subject matter experts in regulatory, quality, and cybersecurity offers a pragmatic solution for startups and smaller companies to navigate complex compliance landscapes and avoid common pitfalls.

    What risks do you take when cybersecurity is left off your development roadmap?

    In this episode, Christian, Trevor and guest Jim Goodmiller explore how cybersecurity intersects with regulatory expectations and quality systems, creating new challenges and opportunities for MedTech innovators. Jim helps to explain why founders must integrate cybersecurity from concept through commercialization, especially as FDA scrutiny increases.

    Key points:

    00:48 Why cybersecurity now influences every part of the regulatory landscape.

    04:48 How technologies can create serious safety and compliance risks when not fully vetted.

    10:45 Cybersecurity as a mandatory component of regulatory planning.

    14:52 The need for iterative penetration testing

    22:16 Challenges of upgrading legacy devices

    25:37 Avoiding serious legal consequences.

    29:29 Preparing a complete roadmap for investor confidence

    40:08 The role of communication

    Notable quotes

    “Cybersecurity, you can't put it on a roadmap in a quarter because it's more of an iterative thing that has to be from the inception to the disposal of the device along the whole way with various gates.”
    - Christian Espinosa
    “If you are going to move your product to some form of commercialization, you have to have a cybersecurity plan. You have to have a roadmap and a direction.”
    - Jim Goodmiller
    “I think that new technology, in general, should go through a little bit more of a proving cycle before it should be used in the MedTech space and the life sciences space.”
    - Trevor Slattery
    “With cybersecurity, there are always findings in one way or another. So, preparing for that fact, 'we're going to have to fix things, we should get ahead of this,' is a little bit different.”
    - Trevor Slattery

    Frequently asked questions

    Bring this work to your device

    Need help with fda postmarket cybersecurity?

    Blue Goat Cyber delivers fda postmarket cybersecurity services for medical device manufacturers - from threat modeling to FDA-ready reports.

    FDA Postmarket Cybersecurity Services

    More on FDA Postmarket Cybersecurity

    Ready when you are

    Get FDA cleared without the cybersecurity headaches.

    30-minute strategy session. No cost, no commitment - just answers from people who've shipped 250+ FDA submissions.